Century Therapeutics (IPSC) Non-Current Debt (2020 - 2022)
Century Therapeutics (IPSC) posted quarterly Non-Current Debt of $3.7 million for Q4 2022, down 58.0% year-over-year from $8.9 million in Q4 2021, and down 39.06% quarter-over-quarter from $6.1 million in Q3 2022.
Century Therapeutics (IPSC) Non-Current Debt (2020 - 2022) Analysis & Trends
Century Therapeutics (IPSC) has reported Non-Current Debt for 3 consecutive years, with $3.7 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Non-Current Debt fell 58.0% year-over-year to $3.7 million; the TTM figure through Dec 2022 stood at $3.7 million (down 58.0% YoY), while the FY2022 annual figure was $3.7 million, down 58.0% from the prior year.
- Non-Current Debt declined to $3.7 million in Q4 2022 per IPSC's latest filing, from $6.1 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $10.0 million in Q1 2022 and bottomed at $3.7 million in Q4 2022.
- Historically, Non-Current Debt has averaged $7.8 million across 3 years, with a median of $8.7 million in 2021.
- Annual changes were most pronounced in 2021 — Non-Current Debt dropped 7.61% — and 2022, when it sank 58.0%.
- Century Therapeutics' Non-Current Debt stood at $9.6 million in 2020, then retreated by 7.61% to $8.9 million in 2021, then tumbled by 58.0% to $3.7 million in 2022.
- Business Quant data shows IPSC's Non-Current Debt at $3.7 million in Q4 2022, $6.1 million in Q3 2022, and $8.5 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 3.74 Mn |
| Sep 30, 2022 | 6.14 Mn |
| Jun 30, 2022 | 8.50 Mn |
| Mar 31, 2022 | 10.02 Mn |
| Dec 31, 2021 | 8.90 Mn |
| Dec 31, 2020 | 9.64 Mn |